Varenicline in the management of smoking cessation: a single technology appraisal

Hind D, Tappenden P, Peters J, Kenjegalieva K
Record ID 32013000705
Authors' recommendations: Varenicline is likely to be clinically effective and cost-effective if one assumes, as the clinical trials and the manufacturer's model do, that each user makes a single quit attempt. The key area of uncertainty concerns the long-term experience of subjects who have remained abstinent from smoking beyond 12 months. The health economic model makes an assumption of sustained benefit for the remaining 81 years of the time horizon. The validity of the assumption of sustained benefit between treatment groups is unclear.
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Clinical Trials as Topic
  • Quality-Adjusted Life Years
  • Varenicline
  • Antidepressive Agents, Second-Generation
  • Benzazepines
  • Bupropion
  • Nicotinic Agonists
  • Quinoxalines
  • Smoking Cessation
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.